BOEHRINGER-INGELHEIM
13.1.2021 10:03:25 CET | Business Wire | Press release
Boehringer Ingelheim, a global leader in animal health, is proud to announce that it has received marketing authorization from the EMA (European Medicine Agency) and European Commission for its NexGard® COMBO topical solution for cats. This innovative parasiticide will be available in the European Union shortly. NexGard® COMBO offers unparalleled protection for cats: It kills a broader range of parasites than any other isoxazoline-based cat parasiticide currently available on the market.
As such, NexGard® COMBO eliminates fleas, ticks, and ear mites, prevents heartworm disease and treats hookworm, roundworm, vesical worm, lungworm, as well as tapeworm infections. Active ingredients are esafoxolaner (the new generation of afoxolaner), eprinomectin, and praziquantel.
Infection by both external and internal parasites is common in cats and occurs at a significant rate worldwide.1,2 NexGard® COMBO provides efficacy against both types of parasites with a triple action formula – making compliance to treatment recommendations easier for cat owners. Application is also easy for cat owners with the syringe-shaped pipette.
Multiple clinical studies supported the approval and showed that NexGard® COMBO:
- Kills fleas before they can lay eggs and maintains efficacy for one month3
- Kills the most common tick species in cats: Ixodes scapularis for one month and Ixodes ricinus for five weeks3
- Is 100 percent effective in preventing heartworm disease4
- Is 100 percent effective against Echinococcus multilocularis 4
- Exceeds the 90 percent regulatory threshold for other internal parasite efficacy4
- Is safe for cats and kittens as young as 8 weeks and weighing at least 0.8kg3
“Boehringer Ingelheim has always been on the cutting edge of research and development in the parasiticide space, and we’re thrilled to continue that pioneering approach with the granting of a marketing authorization for NexGard® COMBO for cats in the EU. NexGard® COMBO is the first isoxazoline-based full endectocide developed specifically for cats,” shares Dr. Craig Beck, Global Franchise Head NexGard® , Boehringer Ingelheim Animal Health. “We’re dedicated to being the global leader in feline health care and the launch of NexGard® COMBO for cats expands our trusted feline product portfolio.”
The NexGard® family of products is the global #1 pet parasiticides brand in sales5 and has been used worldwide over 465 million times in dogs6 . Now, for the first time, the brand has expanded to feline parasite control products.
Please click on the link for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/nexgard-combo-cats-ema-marketing-authorization
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005334/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ (NYSE: NIQ) Unveils Six New AI-Powered Capabilities at C360, Executing on Its Vision for Agentic Commerce9.6.2026 21:00:00 CEST | Press release
New capabilities help organizations operationalize trusted market intelligence across enterprise AI environments and workflows, while preparing for the future of agentic commerce NielsenIQ (NYSE: NIQ) today unveiled six new AI-powered capabilities at C360, the company's flagship client and industry event, marking a major milestone in the execution of NIQ’s AI strategy. Thenew capabilities help brands, retailers, and other organizations operationalize trusted market intelligence across enterprise workflows, AI environments, and the emerging world of agentic commerce. NIQ’s AI value creation strategy is built on two foundational principles: Delivering The Full View™: Combining the industry’s broadest and deepest datasets, advanced AI models, and rich content to help organizations unlock actionable insights and drive AI innovation at scale. Enabling AI-Powered Capabilities: Delivering trusted intelligence and proprietary IP through NIQ’s advanced AI applications, assistants, and agents em
H55 Delivers Certification-Grade Propulsion Battery Modules to Pratt & Whitney Canada, Supporting Demonstration of Hybrid-Electric Aircraft Technology9.6.2026 17:31:00 CEST | Press release
Production-conforming systems manufactured in a regulator-approved facility mark H55’s transition from technology development to commercialization of certification-grade energy storage solutions for hybrid-electric aviation. H55 today announced the delivery of certification-grade propulsion battery modules to Pratt & Whitney Canada in support of the RTX Hybrid-Electric Flight Demonstrator — a milestone that further validates H55’s transition from technology development to industrial-scale execution and represents an important step in the commercialization of the company’s certification-grade energy storage technologies for hybrid-electric aerospace applications. Pratt & Whitney is an RTX business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609825006/en/ H55 Adagio Battery Modules in Pratt & Whitney Canada Hangar ©RTX The delivery represents more than hardware integration. It demonstrates H55’s ability to manufacture p
New Polymorph of Indomethacin Discovered9.6.2026 17:00:00 CEST | Press release
- Joint Research Involving Rigaku Published in Crystal Growth & Design - Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced that the results of a joint research project conducted with Shionogi & Co., Ltd., JEOL Ltd., and Meiji Pharmaceutical University have been published in Crystal Growth & Design, a world-renowned international journal in the field of crystallography. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609347405/en/ Cover of the June 2026 issue of Crystal Growth & Design, featuring this research. This research uncovered a previously unknown polymorph (κ-form) of indomethacin, a widely used pain relief and anti-inflammatory drug. The research team also conducted structural analysis and characterization of the newly identified crystal form. Although indomethacin has
SLB Collaborates with Qualcomm on Edge AI Solutions for Energy Operations9.6.2026 16:28:00 CEST | Press release
Collaboration combines edge computing and energy workflows to support real-time operational decision-making Global energy technology company SLB (NYSE: SLB) today announced a memorandum of understanding with Qualcomm Technologies, Inc. to enable edge AI solutions for the energy industry, supporting real-time operational decision-making across wells, facilities and production systems. The collaboration combines Qualcomm Technologies’ low-power edge computing and AI processing capabilities, with SLB’s Agora™ edge AI and IoT solutions developed for remote and operationally complex environments. “Together, SLB and Qualcomm Technologies aim to help operators apply AI more effectively across energy infrastructure,” said Rakesh Jaggi, president, Digital, SLB. “Many energy operations rely on real-time decision-making in remote environments where connectivity and responsiveness directly affect performance. AI systems designed around the realities of energy operations can help support more consi
RevBits and Stony Brook University’s Ethos Lab Establish a Collaborative Partnership to Further the Field of Cyber Security Education and Application9.6.2026 16:15:00 CEST | Press release
Through the partnership, RevBits will provide its full suite of cybersecurity solutions to Stony Brook University’s Ethos Lab, to deliver the capability to advance student education and equip them with the knowledge needed to face modern cyber threats in a realistic, contained environment. Stony Brook University’s (SBU) Ethos Lab, in the College of Engineering and Applied Sciences Department of Computer Science, recently announced a collaborative partnership with RevBits, LLC. Through the partnership, SBU’s Ethos Lab will utilize the RevBits solutions suite to build computer science labs and a cybersecurity-focused curriculum, reinforcing lessons from the classroom. The platform simulates environments containing five major threat landscapes, including Endpoint Security, Privileged Access Management, Email Security, Zero Trust Network and Deception Technology. SBU’s Department of Computer Science was recently designated as a National Center of Academic Excellence in Cybersecurity Resear
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
